Advertisement

Molecular Medicine

, Volume 17, Issue 1–2, pp 95–102 | Cite as

Gene Expression Changes in Multiple Sclerosis Relapse Suggest Activation of T and Non-T Cells

  • J. William Lindsey
  • Sandeep K. Agarwal
  • Filemon K. Tan
Research Article

Abstract

A defining feature of multiple sclerosis (MS) is the occurrence of clinical relapses separated by periods of clinical stability. Better understanding of the events underlying clinical relapse might suggest new approaches to treatment. The objective of this study was to measure changes in the expression of RNA in the blood during relapse. We used microarrays to measure mRNA expression in paired samples from 14 MS patients during clinical relapse and while stable. Seventy-one transcripts changed expression at the P< 0.001 significance level. The most notable finding was decreased expression of transcripts with regulatory function, expressed primarily in non-T cells. These decreased transcripts included the interleukin-1 receptor antagonist, which had a corresponding decrease in the protein concentration in serum. Transcripts with increased expression were expressed primarily in T cells. Pathways analysis suggested involvement of the cytokine network, coagulation and complement cascades, IL-10 signaling and NF-κB signaling. We conclude that there are alterations of mRNA expression in both T cells and non-T cells during MS relapse.

Notes

Acknowledgments

We thank Landon Hatfield, Uffaf Khan, and the University of Texas-Houston Microarray Core Facility for technical assistance. This work was funded in part by the Clayton Foundation for Research.

References

  1. 1.
    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. (2000) Multiple sclerosis. N. Engl. J. Med. 343:938–52.CrossRefGoogle Scholar
  2. 2.
    Sibley WA, Bamford CR, Clark K. (1985) Clinical viral infections and multiple sclerosis. Lancet. 1:1313–5.CrossRefGoogle Scholar
  3. 3.
    Buljevac D, et al. (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 125:952–60.CrossRefGoogle Scholar
  4. 4.
    Polman CH, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899–910.CrossRefGoogle Scholar
  5. 5.
    Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. (2004) Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 55:410–7.CrossRefGoogle Scholar
  6. 6.
    Arthur AT, et al. (2008) Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med. Genet. 9:17.CrossRefGoogle Scholar
  7. 7.
    Malmestrom C, et al. (2008) Relapses in multiple sclerosis are associated with increased CD8(+) T-cell mediated cytotoxicity in CSF. J. Neuroimmunol 196:159–65.CrossRefGoogle Scholar
  8. 8.
    Satoh J, Misawa T, Tabunoki H, Yamamura T. (2008) Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis. Markers. 25:27–35.CrossRefGoogle Scholar
  9. 9.
    Wright GW, Simon RM. (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics. 19:2448–55.CrossRefGoogle Scholar
  10. 10.
    Dillon SP, D’Souza A, Kurien BT, Scofield RH. (2009) Systemic lupus erythematosus and C1q: A quantitative ELISA for determining C1q levels in serum. Biotechnol. J. 4:1210–4.CrossRefGoogle Scholar
  11. 11.
    Lu JH, et al. (2008) The classical and regulatory functions of C1q in immunity and autoimmunity. Cell. Mol. Immunol. 5:9–21.CrossRefGoogle Scholar
  12. 12.
    Christophi GP, et al. (2009) Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab. Invest. 89:742–59.CrossRefGoogle Scholar
  13. 13.
    Achiron A, Feldman A, Mandel M, Gurevich M. (2007) Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. N. Y. Acad. Sci. 1107:155–67.CrossRefGoogle Scholar
  14. 14.
    Gurevich M, Tuller T, Rubinstein U, Or-Bach R, Achiron A. (2009) Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med. Genomics. 2:46.CrossRefGoogle Scholar
  15. 15.
    Brynedal B, et al. (2009) Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol. Dis. 37:613–21.CrossRefGoogle Scholar
  16. 16.
    Ramanathan M, et al. (2001) In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 116:213–9.CrossRefGoogle Scholar
  17. 17.
    Corvol JC, et al. (2008) Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc. Natl. Acad. Sci. U. S. A. 105:11839–44.CrossRefGoogle Scholar
  18. 18.
    Bomprezzi R, et al. (2003) Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12:2191–9.CrossRefGoogle Scholar
  19. 19.
    Iglesias AH, et al. (2004) Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150:163–77.CrossRefGoogle Scholar
  20. 20.
    De Jager PL, et al. (2009) Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41:776–82.CrossRefGoogle Scholar
  21. 21.
    (2009) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 41:824–8.Google Scholar
  22. 22.
    Cojocaru M, Serbanescu A, Cojocaru IM. (1993) Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis. Rom. J. Intern. Med. 31:131–7.PubMedGoogle Scholar
  23. 23.
    Glass WG, Sarisky RT, Vecchio AM. (2006) Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J. Interferon Cytokine Res. 26:511–20.CrossRefGoogle Scholar
  24. 24.
    Skundric DS, Cai J, Cruikshank WW, Gveric D. (2006) Production of IL-16 correlates with CD4+Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J. Neuroinflammation. 3:13.CrossRefGoogle Scholar
  25. 25.
    Skundric DS, Zhou W, Cruikshank WW, Dai R. (2005) Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J. Autoimmun. 25:206–14.CrossRefGoogle Scholar
  26. 26.
    Annibali V, et al. (2007) Gene expression profiles reveal homeostatic dynamics during interferonbeta therapy in multiple sclerosis. Autoimmunity. 40:16–22.CrossRefGoogle Scholar
  27. 27.
    Feakes R, et al. (2000) Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. J. Neuroimmunol. 105:96–101.CrossRefGoogle Scholar
  28. 28.
    Comabella M, et al. (2008) Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. J. Neurol. 255:1136–41.CrossRefGoogle Scholar
  29. 29.
    Burger D, et al. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 106:4355–9.CrossRefGoogle Scholar
  30. 30.
    Nicoletti F, et al. (1996) Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine. 8:395–400.CrossRefGoogle Scholar
  31. 31.
    Dettke M, Scheidt P, Prange H, Kirchner H. (1997) Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J. Clin. Immunol. 17:293–300.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • J. William Lindsey
    • 1
  • Sandeep K. Agarwal
    • 2
  • Filemon K. Tan
    • 2
  1. 1.Department of Neurology, Division of RheumatologyUniversity of Texas Health Science Center at HoustonHoustonUSA
  2. 2.Department of Medicine, Division of RheumatologyUniversity of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations